← All trials
NCT02168842
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2014
- Primary completion
- Nov 1, 2018
- Completion date
- Mar 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 336
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of RochesterLead sponsor
- Northwestern UniversityOverall official - principal investigator
- University of RochesterOverall official - principal investigator
- University of RochesterReponsible party - principal investigator
- National Institute of Neurological Disorders and Stroke (NINDS)Collaborator
- Michael J. Fox Foundation for Parkinson's ResearchCollaborator
- The Parkinson Study GroupCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.